Last reviewed · How we verify

NCT05872555

Side Effects of Psychiatric Medications - a Nested Case Control Cohort Historical Prospective Study

Status unknown Last updated 4 March 2024
What this trial tests

trial testing Psychiatric Drugs in Psychotic Disorders in 22,777 participants. Status unknown.

Timeline
26 March 2023
Primary endpoint
1 June 2024
1 January 2025

Quick facts

Lead sponsorMark Weiser, MD, Principal Investigator
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment22,777
Start date26 March 2023
Primary completion1 June 2024
Estimated completion1 January 2025
Sites1 location across Israel

Drugs / interventions tested

Conditions studied

Sponsor

Mark Weiser, MD, Principal Investigator — full company profile →

Who can join

18 and older, any sex, with Psychotic Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is designed to fill in the gaps in current knowledge by providing a more inclusive and comprehensive understanding of the potential associations between different psychiatric medications, including antipsychotics (APs), Antidepressants, Benzodiazepines and mood stabilizers, and negative outcomes, as previous research has often been limited to data from clinical trials. The primary objectives of the study include assessing the association between different psychiatric medications and long-term major negative medical conditions and events. Additionally, the study aims to assess the association between different psychiatric medications and long-term negative metabolic events such as diabetes, obesity, hypertension and hypercholesterolemia. This study aims to investigate the potential long-term negative effects of different psychiatric medications on patients with schizophrenia, schizoaffective disorder, depression, bipolar disorder and dementia, patients with other diagnoses, as well as patients receiving different psychiatric medications who do not have a psychiatric diagnosis. The study will be done using data from the Clalit Health Services (CHS) database, which is the largest provider of health insurance in Israel, serving approximately 55% of the population. This database provides access to all diagnoses and blood tests for the duration of the study, which allows for accurate tracking of patient outcomes over time. Inclusion criteria include being diagnosed with schizophrenia/schizoaffective disorder/bipolar disorder/depression, dementia, other psychiatric diagnoses, and/or patients receiving these medications who do not have a psychiatric diagnosis, and use psychiatric medications, including antipsychotics/antidepressants/mood stabilizers/benzodiazepines as registered in the Clalit database. having first prescription of psychiatric medication between 2001 and 2024. The study will look at those patients included and will follow them using the CHS database to assess these different medical and or metabolic side-effects and the appearance of major negative and major metabolic events, as well as abnormal metabolic measurements.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Psychotic Disorders

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05872555.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing